Biora Therapeutics (Biora Therapeutics) Debt-to-Equity : -0.47 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Biora Therapeutics Debt-to-Equity?

Biora Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.87 Mil. Biora Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $44.55 Mil. Biora Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-101.42 Mil. Biora Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was -0.47.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Biora Therapeutics's Debt-to-Equity or its related term are showing as below:

BIOR' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.97 Med: -1.38 Max: -0.47
Current: -0.47

During the past 6 years, the highest Debt-to-Equity Ratio of Biora Therapeutics was -0.47. The lowest was -1.97. And the median was -1.38.

BIOR's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.145 vs BIOR: -0.47

Biora Therapeutics Debt-to-Equity Historical Data

The historical data trend for Biora Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biora Therapeutics Debt-to-Equity Chart

Biora Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.88

-1.50

-1.49

-1.26

-0.47

Biora Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-1.26	-1.24	-1.08	-0.69	-0.47

Competitive Comparison of Biora Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Biora Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biora Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biora Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Biora Therapeutics's Debt-to-Equity falls into.

Biora Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Biora Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.872	+	44.554)	/	-101.421
	=	-0.47

Biora Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.872	+	44.554)	/	-101.421
	=	-0.47

Biora Therapeutics (NAS:BIOR) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Biora Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Biora Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Biora Therapeutics (Biora Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biora Therapeutics Inc (NAS:BIOR) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

4ZU0:Germany 4ZU0:Germany

Address

4330 La Jolla Village Drive, Suite 300, San Diego, CA, USA, 92122

Website

https://www.bioratherapeutics.com

Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology. Geographically, it operates only in the United States.

Executives

Athyrium Opportunities Iii Co-invest 1 Lp	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Surbhi Sarna	director	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Aditya P. Mohanty	director, officer: Chief Executive Officer	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Jill Ann Howe	director	C/O DTX PHARMA, INC., 10655 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Athyrium Capital Management, Lp	10 percent owner	505 FIFTH AVENUE, FLOOR 18, NEW YORK NY 10017
Athyrium Opportunities Fund (a) Lp	10 percent owner	605 THIRD AVENUE, 22ND FLOOR, NEW YORK NY 10158
Hutan Hashemi	officer: Chief Compliance Officer	4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Damon Silvestry	officer: Chief Operating Officer	4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Jeffrey D. Alter	director	4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Athyrium Opportunities Iii Acquisition Lp	10 percent owner	505 FIFTH AVENUE, 18TH FLOOR, NEW YORK NY 10017
Harry Stylli	director, officer: Chairman & CEO	3595 JOHN HOPKINS CT, SAN DIEGO CA 92121
Matthew T Cooper	officer: Chief Scientific Officer	4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO CA 92122
Athyrium Opportunities Advisers Llc	10 percent owner	1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104
Athyrium Opportunities Associates Gp Llc	10 percent owner	1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104
Athyrium Opportunities Associates Lp	10 percent owner	1209 AVENUE OF THE AMERICAS, NEW YORK NY 10104